Table 3.
Demographic and clinical data for patients biopsied before, during, and after T1R
| Patient no. | Sex | Age (yr) at 1st biopsy | Leprosy type | Interval between 1st and 2nd biopsies (mo) | Type 1 reaction |
Interval between 2nd and 3rd biopsies (mo) | ||
|---|---|---|---|---|---|---|---|---|
| 1st | 2nd | 3rd | ||||||
| 1 | F | 34 | BB | 12 | No | Yes | NDc | |
| 2 | F | 64 | BL | 12 | No | Yes | ND | |
| 3 | M | 50 | BL | 36 | No | Yes | No | 48 |
| 5a | M | 61 | BL | 1 | No | Yes | No | 22 |
| 6 | M | 46 | BL | 54 | No | Yes | ND | |
| 9b | M | 51 | BL | 42 | No | Yes | ND | |
| 4 | F | 44 | LL-BL | 12 | No | No | ND | |
| 7 | F | 63 | BL | 11 | No | No | ND | |
| 8 | M | 32 | BL | 13 | No | No | ND | |
a
Patient was treated with infliximab prior to diagnosis of leprosy; the agent was discontinued 1 month prior to the onset of T1R.
b
Immunostaining studies only.
c
ND, not done.